

SSX (E5A2C) Rabbit mAb (Carboxyterminal Antigen)



Orders:	877-616-CELL (2355) orders@cellsignal.com			
Support:	877-678-TECH (8324)			
Web:	info@cellsignal.com cellsignal.com			

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID: #016384	Entrez-Gene Id:	
IHC-P		Endogenous	25	Rabbit Igo	#0000	0750	
Product Usage Information		Application Western Blotting Immunoprecipitation IHC Leica Bond Immunohistochemistry	r (Paraffin)		Dilution 1:1000 1:100 1:100 - 1:44 1:50 - 1:20	00 0	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. <i>Do not aliquot the antibody.</i>					
Specificity/Sens	sitivity	SSX (E5A2C) Rabbit mAb (Carboxy-terminal Antigen) recognizes endogenous levels of total SSX1-4 proteins. This antibody also detects the SS18-SSX fusion protein.				total SSX1-4	
Source / Purific	ation	Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gln173 of human SSX1 protein.					
Background		The SS18-SSX fusion proteins are a result of in-frame fusions that fuse the SS18 gene on chromosome 18 with X chromosome genes SSX1, SSX2, and to a lesser extent SSX4 (1). Human synovial sarcoma (SS) accounts for 8-10% of all soft tissue malignancies and 95% of these malignancies express the recurrent translocation of the SS18 gene on chromosome 18 (1). The N-terminal SNH domain (SYT N-terminal homology domain) of the SS18 protein interacts with SWI/SNF chromatin remodeling complexes via the N terminal region of BRM and BRG1 subunits (2). Studies of the SS18-SSX fusion in SS suggest that endogenous SS18 competes with the mutant SS18-SSX fusion for occupancy in the SWI/SNF complexes resulting in the displacement of the SNF5 (BAF47) subunit. Displacement of the SNF5 subunit results in altered function of the SWI/SNF complex that leads to deregulated expression of genes such as Sox2 in SS (1).					
		While the SSX family of conserved N-terminus of transcriptional represso	proteins is well ch of the SSX family c or (3).	aracterized in SS, little is ontains a KRAB domain v	known outside of th which seems to func	his context. The ction as a	
Background Re	ferences	1. Kadoch, C. and Crabt 2. Perani, M. et al. (2003 3. Lim, F.L. et al. (1998)	ree, G.R. (2013) <i>Ce</i> 8) <i>Oncogene</i> 22, 8 <i>Oncogene</i> 17, 201	// 153, 71-85. 56-67. 3-8.			
Species Reactiv	ity	Species reactivity is dete	ermined by testing	g in at least one approved	d application (e.g., v	vestern blot).	
Western Blot B	uffer	IMPORTANT: For wester TBS, 0.1% Tween® 20 at	rn blots, incubate t 4°C with gentle s	e membrane with diluted primary antibody in 5% w/v BSA, 1X shaking, overnight.			
Applications Ke	y	W: Western Blotting IP: Immunoprecipitation IHC-Bond: IHC Leica Bond IHC-P: Immunohistochemistry (Paraffin)					
Cross-Reactivity	у Кеу	H: Human					
Trademarks and	d Patents	Cell Signaling Technolog	gy is a trademark (of Cell Signaling Technol	ogy, Inc.		
		SignalStain is a register	ed trademark of C	ell Signaling Technology	, Inc.		
		XP is a registered trade	mark of Cell Signa	ling Technology, Inc.			

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.